Related Experiment Video
Updated: Jun 12, 2026
05:26
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Predicting the no-reflow phenomenon following successful percutaneous coronary intervention
L Galiuto1, L Paraggio, G Liuzzo
1Institute of Cardiology, Catholic University of the Sacred Heart, Policlinico A Gemelli, Largo A Gemelli, 8, 00168 Rome, Italy. lgaliuto@rm.unicatt.it
Biomarkers in Medicine
|June 17, 2010
Summary
Biomarkers on admission may predict no-reflow after percutaneous coronary intervention for acute myocardial infarction. Understanding these markers aids in predicting and comprehending the multifactorial mechanisms of this critical condition.
Area of Science:
- Cardiology
- Biomarkers
- Myocardial Infarction
Background:
- Complete myocardial perfusion restoration after acute myocardial infarction artery reopening is not guaranteed.
- The 'no-reflow' phenomenon, characterized by incomplete perfusion, has complex multifactorial pathophysiology.
- Existing methods for predicting no-reflow include angiographic findings and clinical parameters.
Purpose of the Study:
- To investigate the prognostic role of admission biomarkers in predicting no-reflow.
- To enhance the understanding of no-reflow mechanisms through biomarker analysis.
- To identify novel predictive markers for no-reflow post-percutaneous coronary intervention.
Main Methods:
- Analysis of various biomarkers measured on admission.
- Correlation of biomarker levels with the occurrence of no-reflow.
- Evaluation of predictive capabilities of biomarkers for no-reflow post-successful percutaneous coronary intervention.
Main Results:
- Certain admission biomarkers show potential in predicting no-reflow.
- Biomarkers offer insights into the pathogenetic components of no-reflow.
- Biomarker profiles may improve risk stratification for no-reflow.
Conclusions:
- Admission biomarkers can serve as valuable predictors of no-reflow.
- Biomarker assessment can contribute to a deeper understanding of no-reflow pathophysiology.
- Integrating biomarkers into clinical practice may optimize management of patients with acute myocardial infarction.
